Aclidinium: A guide to its use in chronic obstructive pulmonary disease in the EU

Drugs and Therapy Perspectives

Volumn 29, Issue 2, 2013, Pages 34-39

  Scott, Lesley J ^a   Lyseng Williamson, Katherine A ^a   Frampton, James E ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; PLACEBO;

ANTICHOLINERGIC SYNDROME; ARTICLE; ASTHMA; BACKACHE; BREAST FEEDING; BRONCHITIS; BRONCHODILATATION; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; COUGHING; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GERIATRIC PATIENT; HEADACHE; HEALTH STATUS; HEART DEATH; HEART INFARCTION; HUMAN; HYPERTENSION; INSPIRATORY CAPACITY; KIDNEY DISEASE; LIVER DISEASE; LONG TERM CARE; LUNG FUNCTION; MEAN RESIDENCE TIME; METERED DOSE INHALER; PREGNANT WOMAN; RECEPTOR BLOCKING; RHINOPHARYNGITIS; TREATMENT INDICATION; TREATMENT WITHDRAWAL; XEROSTOMIA;

EID: 84876920395     PISSN: 11720360     EISSN: 11791977     Source Type: Journal    
DOI: 10.1007/s40267-013-0014-3     Document Type: Article

References (14)

1. Global Initiative for Chronic Obstructive Lung Disease, Inc. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (revised 2011). http://www.goldcopd.org/uploads/users/files/ GOLD-Report-2011-Feb21.pdf. Accessed 12 Dec 2012.
2. Frampton JE. Aclidinium: in chronic obstructive pulmonary disease. Drugs. 2012;27(15):1999-2011.
3. ® 322 micrograms inhalation powder: summary of product characteristics. London: European Medicines Agency; 2012.
4. Gavalda A, Miralpeix M, Ramos I, et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther. 2009;331(2):740-51.
5. Tudorza™ Pressair™ (aclidinium bromide inhalation powder): US prescribing information. St. Louis: Forest Pharmaceuticals, Inc., 2012.
6. Kerwin EM, D'Urzo AD, Gelb AF, et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012;9(2):90-101.
7. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012;40(4):830-6.
8. Jones P, Agusti A, Bateman E, et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in symptoms and health status in the ATTAIN study [abstract]. Chest. 2011;140(4):547A.
9. Gelb AF, Make BJ, Tashkin DP, et al. Long-term efficacy and safety of twice-daily aclidinium bromide in COPD patients: a one-year study [abstract]. Am J Respir Crit Care Med. 2012;185:A2256.
10. Pulmonary Allergy Drugs Advisory Committee Meeting, February 23, 2012. NDA 202-450: aclidinium bromide for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including bronchitis and emphysema. Bethesda: US Food and Drug Administration; 2012.
11. Lasseter KC, Aubets J, Chuecos F, et al. Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects. J Clin Pharmacol. 2011;51(6):923-32.
12. ® in patients with COPD [abstract]. Chest. 2012;142(4):717A.
13. Singh D, Magnussen H, Kirsten A, et al. A randomized, placebo- and active-controlled dose finding study of aclidinium bromide administered twice a day in COPD patients. Pulm Pharmacol Ther. 2012;25(3):248-53.
14. Hass C, Engdahl K, Albert W, et al. Patient preferences and perceived ease of use in inhaler features: Genuair vs other inhalers [abstract]. Chest. 2010;138(4):484A.